TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate the effects of Remote Ischemic Preconditioning on cognitive function in patients undergoing cardiac surgery compared to control intervention.


Options:
A: Arm Label: Remote ischemic preconditioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote ischemic preconditioning | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Control | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning; Assigned to Arm(s): Remote ischemic preconditioning | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control
B: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Arm Label: CONTROL; Type: SHAM_COMPARATOR; Interventions: Procedure: Control/sham procedure (blood pressure cuff) | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control/sham procedure (blood pressure cuff); Assigned to Arm(s): CONTROL
C: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Arm Label: CONTROL; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): CONTROL
D: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control | Arm Label: Remote ischaemic conditioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote ischaemic preconditioning | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Remote ischaemic conditioning | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brief Intervention in Primary Care for Problem Drug Use and Abuse
Brief Summary: This study will examine the effectiveness of a brief intervention in a primary care setting to reduce drug use or abuse compared to enhanced care as usual.


Options:
A: Arm Label: CapOpus; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy with motivational interviewing, Behavioral: Non-manualized standard treatment | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Non-manualized standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy with motivational interviewing; Assigned to Arm(s): CapOpus | Intervention Type: BEHAVIORAL; Name: Non-manualized standard treatment; Assigned to Arm(s): CapOpus, Treatment as usual
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention using motivational interviewing | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief intervention using motivational interviewing; Assigned to Arm(s): 1
C: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: control group; Type: OTHER; Interventions: Behavioral: Brief Intervention | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): control group, intervention group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral treatment | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral treatment; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease
Brief Summary: This study assessed the efficacy and safety of indacaterol (150 µg once daily \[od\]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Relovair; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI) | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Intervention Type: DRUG; Name: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI); Assigned to Arm(s): Relovair | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: QVA149 + placebo to tiotropium; Type: EXPERIMENTAL; Interventions: Drug: QVA149, Drug: Placebo to tiotropium, Drug: Salbutamol/albuterol | Arm Label: Tiotropium + placebo to QVA149; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Placebo to QVA149, Drug: Salbutamol/albuterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to QVA149, Drug: Placebo to tiotropium, Drug: Salbutamol/albuterol | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 + placebo to tiotropium | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium + placebo to QVA149 | Intervention Type: DRUG; Name: Placebo to QVA149; Assigned to Arm(s): Placebo, Tiotropium + placebo to QVA149 | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): Placebo, QVA149 + placebo to tiotropium | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): Placebo, QVA149 + placebo to tiotropium, Tiotropium + placebo to QVA149
D: Arm Label: Indacaterol 150 μg and tiotropium 18 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Tiotropium 18 μg | Arm Label: Tiotropium 18 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg, Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg and tiotropium 18 μg | Intervention Type: DRUG; Name: Tiotropium 18 μg; Assigned to Arm(s): Indacaterol 150 μg and tiotropium 18 μg, Tiotropium 18 μg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Tiotropium 18 μg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease
Brief Summary: This study assessed the efficacy and safety of indacaterol (150 µg once daily \[od\]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Indacaterol 75 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 75 μg | Arm Label: Placebo to indacaterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 75 μg; Assigned to Arm(s): Indacaterol 75 μg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Placebo to indacaterol
B: Arm Label: Indacaterol 75 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Indacaterol 75 µg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Placebo
C: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to Salmeterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Indacaterol, Drug: Placebo to Salmeterol | Arm Label: Salmeterol 50 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 μg, Drug: Placebo to Indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Salmeterol 50 μg; Assigned to Arm(s): Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Indacaterol; Assigned to Arm(s): Placebo, Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Salmeterol; Assigned to Arm(s): Indacaterol 150 μg, Placebo
D: Arm Label: Indacaterol 150 μg and tiotropium 18 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Tiotropium 18 μg | Arm Label: Tiotropium 18 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg, Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg and tiotropium 18 μg | Intervention Type: DRUG; Name: Tiotropium 18 μg; Assigned to Arm(s): Indacaterol 150 μg and tiotropium 18 μg, Tiotropium 18 μg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Tiotropium 18 μg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Vaccinating Health Hutterite Children Against Influenza Prevent Influenza in Other Hutterite Colony Members: A Randomized Cluster Trial
Brief Summary: The goal of this randomized clinical trial is to determine whether immunizing children in Hutterite colonies with inactivated influenza vaccine can prevent influenza and its complications in other colony members. Furthermore, the study will assess the indirect benefit to Hutterites at high risk of complications. The study is a blinded, cluster randomized controlled trial among Hutterite colonies to test the hypothesis that high immunization rates (\>70%) of healthy children with inactivated influenza vaccine reduces transmission of influenza to other colony members. Randomization of these homogeneous, moderately sized colonies where there is regular spread facilitated by a communal lifestyle, but limited re-introduction because of relative isolation from outside community, represents a unique opportunity to test the hypothesis of indirect benefit under close to ideal conditions. The primary outcome will be laboratory-confirmed influenza. Secondary outcomes include influenza-like illness, otitis media, physician visits, antimicrobial prescriptions, absenteeism, lower respiratory tract infection, hospitalizations, and death.


Options:
A: Arm Label: Influenza; Type: EXPERIMENTAL; Interventions: Biological: Influenza vaccination | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Biological: Hepatitis A Vaccine | Intervention Type: BIOLOGICAL; Name: Influenza vaccination; Assigned to Arm(s): Influenza | Intervention Type: BIOLOGICAL; Name: Hepatitis A Vaccine; Assigned to Arm(s): Control
B: Arm Label: MEDI3414 [Influenza A (H1N1) vaccine]; Type: EXPERIMENTAL; Interventions: Biological: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal] | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]; Assigned to Arm(s): MEDI3414 [Influenza A (H1N1) vaccine] | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: MEDI3414 [Influenza A (H1N1) vaccine]; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI3414 [Influenza A(H1N1) live attenuated, intranasal] | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]; Assigned to Arm(s): MEDI3414 [Influenza A (H1N1) vaccine] | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BIOLOGICAL; Name: CAIV-T; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Double-Blind, Multi-Center, Placebo-Controlled, Randomized Withdrawal, Safety and Efficacy Study of SPD489 in Adults Aged 18-55 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Brief Summary: The primary objective of this study is to evaluate the maintenance of efficacy, as measured by Adult ADHD Rating Scale with Prompts (Adult ADHD-RS with prompts) and Clinical Global Impression - Severity (CGI-S) scores, through a randomized withdrawal design when subjects with ADHD have been on stable treatment with commercial SPD489 for a minimum of 6 months and are maintained on their screening dose of commercial SPD489.


Options:
A: Arm Label: SPD489; Type: ACTIVE_COMPARATOR; Interventions: Drug: SPD489 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: SPD489; Assigned to Arm(s): SPD489 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: NRP104; Assigned to Arm(s): N/A
C: Arm Label: LDX Treatment; Type: EXPERIMENTAL; Interventions: Drug: LDX Treatment | Intervention Type: DRUG; Name: LDX Treatment; Assigned to Arm(s): LDX Treatment
D: Arm Label: SPD489; Type: EXPERIMENTAL; Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SPD489 (Lisdexamfetamine dimesylate); Assigned to Arm(s): SPD489 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of a HPV Vaccine (GSK 580299) in Healthy Female Subjects
Brief Summary: Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. This study is designed to evaluate the long-term immunogenicity and safety of the 580299 HPV vaccine up to 10 years after administration of the first dose of HPV vaccine (Month 0) administered in the primary study 580299/013. This protocol posting deals with objectives \& outcome measures of the extension phase from Month 60 to Month 120. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT00196924). The objectives \& outcome measures of the extension phase up to Month 48 are presented in a separate protocol posting (NCT00316706).


Options:
A: Arm Label: A: HAART naive or no HAART in past 6 months; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV vaccine for strains -6, -11, -16, and -18 | Arm Label: B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV vaccine for strains -6, -11, -16, and -18 | Intervention Type: BIOLOGICAL; Name: HPV vaccine for strains -6, -11, -16, and -18; Assigned to Arm(s): A: HAART naive or no HAART in past 6 months, B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months
B: Arm Label: Cervarix; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix | Arm Label: Gardasil; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gardasil | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil
C: Arm Label: Cervarix Group; Type: OTHER; Interventions: Procedure: Blood sampling | Intervention Type: PROCEDURE; Name: Blood sampling; Assigned to Arm(s): Cervarix Group
D: Arm Label: Quadrivalent Human Papillomavirus (HPV) Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Matching Placebo | Intervention Type: BIOLOGICAL; Name: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): Quadrivalent Human Papillomavirus (HPV) Vaccine | Intervention Type: BIOLOGICAL; Name: Matching Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Behavioral Therapy for Depression After Traumatic Brain Injury
Brief Summary: The purpose of this study is to test the effectiveness of a telephone-based and in-person Cognitive Behavioral Therapy (CBT) intervention for treating Major Depressive Disorder (MDD) following Traumatic Brain Injury. Participants are randomly assigned to receive one of the following: 1) Telephone-based CBT, 2) In-person CBT, or 3) Usual care (control).


Options:
A: Arm Label: MBCT Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: MBCT for TBI | Arm Label: MBCT Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MBCT for TBI; Assigned to Arm(s): MBCT Intervention Group
B: Arm Label: Telephone-based CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Cognitive Behavioral Therapy | Arm Label: In-person CBT; Type: EXPERIMENTAL; Interventions: Behavioral: In-person Cognitive Behavioral Therapy | Arm Label: 3: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: In-person Cognitive Behavioral Therapy; Assigned to Arm(s): In-person CBT | Intervention Type: BEHAVIORAL; Name: Telephone Cognitive Behavioral Therapy; Assigned to Arm(s): Telephone-based CBT
C: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Scheduled telephone follow-up | Intervention Type: BEHAVIORAL; Name: Scheduled telephone follow-up; Assigned to Arm(s): 1
D: Arm Label: Treatment Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy | Arm Label: Treatment Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): Treatment Arm 1 | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Treatment Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Trial to Assess Catheter Ablation Versus Rate-Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure
Brief Summary: It is still uncertain what the best treatment is for patients who have both atrial fibrillation (AF) and heart failure. The aim of the study is to help identify the optimal treatment for patients with these two significant medical conditions. This will be performed by comparing two alternative strategies for AF management: catheter ablation (to restore normal rhythm) and medical therapy (to control heart rate, but not aiming ro restore normal rhythm). After random assignment, the effect of each strategy will be assessed by looking for changes in exercise capacity, symptoms, heart pump function, and quality of life during 12 months of follow-up.


Options:
A: Arm Label: Rate control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medication to control ventricular rate in AF | Arm Label: Catheter Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheter Ablation for Persistent Atrial Fibrillation | Intervention Type: DRUG; Name: Medication to control ventricular rate in AF; Assigned to Arm(s): Rate control | Intervention Type: PROCEDURE; Name: Catheter Ablation for Persistent Atrial Fibrillation; Assigned to Arm(s): Catheter Ablation
B: N/A
C: Arm Label: Catheter Ablation; Type: EXPERIMENTAL; Interventions: Procedure: Catheter ablation of persistent atrial fibrillation | Arm Label: Medical treatment alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medical treatment alone | Intervention Type: PROCEDURE; Name: Catheter ablation of persistent atrial fibrillation; Assigned to Arm(s): Catheter Ablation | Intervention Type: DRUG; Name: Medical treatment alone; Assigned to Arm(s): Medical treatment alone
D: Arm Label: medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril, Drug: Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol, Drug: Aldosterone Antagonists - spironolactone | Arm Label: Radiofrequency ablation (RFA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: radiofrequency ablation | Intervention Type: PROCEDURE; Name: radiofrequency ablation; Assigned to Arm(s): Radiofrequency ablation (RFA) | Intervention Type: DRUG; Name: ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril; Assigned to Arm(s): medical therapy | Intervention Type: DRUG; Name: Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol; Assigned to Arm(s): medical therapy | Intervention Type: DRUG; Name: Aldosterone Antagonists - spironolactone; Assigned to Arm(s): medical therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alberta Clinical Trial in Optimizing Hypertension: The RxAction Study
Brief Summary: The purpose of this study is to evaluate the effect of enhanced pharmacist care (patient identification, assessment, education, prescribing/titration of antihypertensive medications and close follow-up) on systolic blood pressure (BP) reduction in patients with poorly controlled hypertension in the community setting.


Options:
A: Arm Label: Advanced care; Type: OTHER; Interventions: Other: Advanced Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Advanced Care; Assigned to Arm(s): Advanced care
B: Intervention Type: BEHAVIORAL; Name: Home BP;secure messaging;pharmaceutical care;; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Lifestyle Counselling; Opinion Leader Influence Statements; Assigned to Arm(s): N/A
D: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Enhanced pharmacist care; Type: EXPERIMENTAL; Interventions: Other: Enhanced pharmacist care | Intervention Type: OTHER; Name: Enhanced pharmacist care; Assigned to Arm(s): Enhanced pharmacist care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alberta Clinical Trial in Optimizing Hypertension: The RxAction Study
Brief Summary: The purpose of this study is to evaluate the effect of enhanced pharmacist care (patient identification, assessment, education, prescribing/titration of antihypertensive medications and close follow-up) on systolic blood pressure (BP) reduction in patients with poorly controlled hypertension in the community setting.


Options:
A: Arm Label: 1; Type: N/A; Interventions: Other: 1 | Arm Label: 2; Type: N/A; Interventions: Other: 2 | Intervention Type: OTHER; Name: 1; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: 2; Assigned to Arm(s): 2
B: Arm Label: Pharmaceutical Education; Type: EXPERIMENTAL; Interventions: Behavioral: Education interventional | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Education interventional; Assigned to Arm(s): Pharmaceutical Education
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Enhanced pharmacist care; Type: EXPERIMENTAL; Interventions: Other: Enhanced pharmacist care | Intervention Type: OTHER; Name: Enhanced pharmacist care; Assigned to Arm(s): Enhanced pharmacist care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Behavioral: knowledge transfer tool | Arm Label: Wait-list group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: knowledge transfer tool; Assigned to Arm(s): Educational intervention

Answer: C